Middle East Generics Producers: Where Are the Big Opportunities? provides newly researched company profiles and competitive intelligence on almost 40 leading generics producers (see full list below) operating in 10 key markets: Bahrain, Egypt, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, UAE.
This is a crucial time in a key market. The Report highlights growth opportunities within the Middle Eastern market which we currently believe is worth US$1.8bn. With BMI’s pharmaceutical analysts forecasting 13% annual growth until at least 2012, we believe that early market entry is crucial to the trajectory of future profit growth.
In order to contextualise opportunities, Middle East Generics Producers: Where Are the Big Opportunities? provides the following for each market (Bahrain, Egypt, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, UAE):
* Clear analysis of key industry trends and growth dynamics, including BMI’s independent 5-year industry forecasts to end-2012.
* Transparent evaluation of business and operational risks to pharmaceuticals companies via BMI’s proprietary country-comparative Industry Business Environment Rating.
* Newly researched company profiles and competitive intelligence on almost 40 leading generics producers (see full list below).
The potential is impressive: We believe that the oil-rich Gulf Cooperation Council (GCC) states hold the biggest potential, with Saudi Arabia’s generics market set to rise by more than 20% annually. More importantly, given the rise in non-communicable chronic diseases - such as diabetes, obesity and heart disease – we see new opportunities for generics players to expand their market beyond core areas.
But growth potential is not uniform across the region: Somewhat counter-intuitively, we believe that the greatest potential lies in the wealthy oil producing states. Here, despite rising wealth, governments are keen to contain cost increases, trends that have been ongoing for many years in non-oil producers such as Lebanon, Jordan and Israel.
Furthermore, there are risks: Our forecasts for rapid industry growth are based in part on expectations that traditional distrust of generics will fade. This has yet to be proven. Furthermore, while BMI’s Oil & Gas analysts believe that oil prices will remain high, generics industry growth is vulnerable to the sustainability of the current energy price boom.
| 
